At a glance
ClinicalIndex Comparison Record- ✓Age >18 years
- ✓Stage IV NSCLC with liver metastases, newly diagnosed including de novo or secondary metastatic disease
- ✓First-line anti-PD-(L)1 based immunotherapy +/- platinum chemotherapy for ≥3 cycles
- ✓Anti-CTLA-4 plus anti-PD-1/PD-L1 combinations allowed
- ✕EGFR mutations
- ✕BRAF mutations
- ✕ALK rearrangements
- ✕ROS-1 rearrangements
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Hepatic Ablation of Metastases to Modulate and Enhance Immunotherapy Response (HAMMER) in NSCLC
In Brief
A Phase 2 clinical trial evaluating L-SABR, Anti-PD-(L)1 based immunotherapy, and 1 other intervention for Non Small Cell Lung Cancer and 4 related conditions. Currently recruiting, targeting 68 participants across 9 sites.
Detailed Summary
The purpose of this study is to see whether adding liver stereotactic ablative radiotherapy/L-SABR to standard drug therapy is better than standard drug therapy alone for people with metastatic non-small cell lung cancer/NSCLC.
Study Details
Timeline
Interventions
L-SABR will be delivered in a week during which the patient receives no chemotherapy. L-SABR can be on the same week or even day as anti-PD-(L)1 therapy.
Standard of care treatment (anti-PD-(L)1 based immunotherapy +/- platinum based chemotherapy
Standard of care treatment (anti-PD-(L)1 based immunotherapy +/- platinum based chemotherapy